Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Wim Tissing

Principal Investigator

Dr. Wim Tissing joined the Princess Máxima Center in 2018 as principal investigator. His research group focuses on supportive care to cope with cancer treatment, increase quality of life and decrese treatment-related mortality.


Wim Tissing did his pediatric training and his pediatric oncology fellowship in the Erasmus MC / Sophia Childrens hospital in Rotterdam, and has been working there as pediatric oncologist since 2000. His PhD (2006) focused on prednisone resistance in childhood ALL. In 2005 he moved to the University Medical Center Groningen. Next to his work as pediatric oncologist, he established his research line on supportive care in childhood oncology. He was appointed associate professor in 2012 and heads the department of pediatric oncology since 2017. Since june 2018 he still works for 2 days per week in the University Medical Center Groningen, and is appointed for 3 days per week in the Princess Máxima Center as principal investigator for supportive care studies and chair of the clinical supportive care group, responsible for the supportive care in the 3 clinical departments. He co-chairs the IPOG group (international group for the development of guidelines for supportive care in pediatric oncology) with Dr Lee Dupuis, Toronto and is associate editor of the Supportive care in cancer journal.

  • Validation of a modified bedside Pediatric Early Warning System score for detection of clinical deterioration in hospitalized pediatric oncology patients

    • jan. 2023
    • Marijn, Soeteman, et al
    • Pediatric Blood and Cancer
  • Fatigue trajectories during pediatric ALL therapy are associated with fatigue after treatment

    • dec. 2022
    • Elin, Irestorm, et al
    • Supportive Care in Cancer
  • Changes in body size and body composition in survivors of childhood cancer

    • dec. 2022
    • Aeltsje, Brinksma, et al
    • Clinical Nutrition
  • The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer

    • dec. 2022
    • J. R., de la Court, et al
    • Infectious Diseases and Therapy
  • Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines

    • dec. 2022
    • Esmée C., de Baat, et al
    • The Lancet Child and Adolescent Health
View all publications